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Summary objective Viral load testing is used in the HIV programme of Chiradzulu, Malawi, to conﬁrm the
diagnosis of immunological failure to prevent unnecessary switching to second-line therapy. Our
objective was to quantify the beneﬁt of this strategy for management of treatment failure in a large
decentralized HIV programme in Africa.
methods Retrospective analysis of monitoring data from adults treated with ﬁrst-line antiretroviral
regimens for >1 year and meeting the WHO immunological failure criteria in an HIV programme in
rural Malawi. The positive predictive value of using immunological failure criteria to diagnose viro-
logical failure (viral load >5000 copies⁄ml) was estimated.
results Of the 227 patients with immunological failure (185 conﬁrmed with a repeat CD4
measurement), 155 (68.2%) had conﬁrmatory viral load testing. Forty-four (28.4%) had viral load
>5000 copies⁄ml and 57 (36.8%) >1000 copies⁄ml. Positive predictive value was 28.4% (95% CI 21.4–
36.2%). Repeat CD4 count testing showed that 41% of patients initially diagnosed with immunological
failure did no longer meet failure criteria.
conclusions Our results support the need for conﬁrming all cases of immunological failure with viral
load testing before switching to second-line ART to optimize the use of resources in developing countries.
keywords Africa, antiretroviral treatment, HIV, resource-limited setting, treatment failure
Introduction
In most resource-limited settings, access to routine viral
load testing to monitor progression of HIV disease is
limited or non-existent because of a combination of lack of
laboratory capacity, prohibitive cost or logistic constraints
(Calmy et al. 2007). This is especially true in sub-Saharan
Africa, which bears the greatest burden of the HIV
epidemic. As a result, evaluation of treatment outcomes
and therapeutic decision-making are generally based on
clinical and immunological ﬁndings. Discordance between
recommended immunological and virological criteria for
failure diagnosis is nevertheless well documented (Moore
et al. 2006; Badri et al. 2008; Mee et al. 2008; Kantor
et al. 2009; Keiser et al. 2009; Reynolds et al. 2009). In
HIV programmes, lack of virological conﬁrmation of
failure may result in premature switching to second-line
antiretroviral therapy (ART), ultimately leading to unnec-
essary exhaustion of available treatment options, and use
of more complicated antiretroviral (ARV) regimens.
Following WHO recommendations (World Health
Organization 2006), viral load testing is used in the HIV
programme of Chiradzulu, Malawi, to conﬁrm the diag-
nosis of immunological failure to prevent unnecessary
switching to second-line therapy. The objective of this
analysis was to quantify the beneﬁt of implementing this
strategy for management of treatment failure in a large
decentralized HIV programme in Africa.
Methods
The Chiradzulu HIV programme
In collaboration with the Malawian Ministry of Health,
Medecins Sans Frontie `res (MSF) has provided free ART to
HIV-infectedpatientsintheruraldistrictofChiradzulusince
2001 (Ferradini et al. 2006). HIV care and treatment are
providedbyclinicalofﬁcersandnursesatthedistricthospital
and in 10 peripheral primary health facilities. Criteria for
startingARTarethediagnosisofaWHOclinicalstage3or4
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Health and Population 2008). The standard ﬁrst-line ART
regimen is a generic ﬁxed-dose-combination of stavudine
(d4T), lamivudine (3TC) and nevirapine (NVP).
Since 2007, routine CD4 cell testing is performed for all
patients prior to ART initiation, at 6 and 12 months after
the start of therapy, and annually thereafter. Since 2008,
viral load testing is used for conﬁrmation of immunological
failure before switching to second line. Laboratory capac-
ity limits the number of viral load tests to a maximum
of 100 per month.
Study design and data collection
A longitudinal analysis of routine data from adults treated
with ﬁrst-line ART in the programme was performed.
Individual clinical and immunological patient information,
including age, sex, weight, height, WHO clinical stage,
ART regimen prescriptions with dates of administration,
and CD4 cell and viral load measurements, was routinely
collected at each HIV consultation on standardized forms
and entered into the FUCHIA software (Epicentre, Paris,
France). All patient identiﬁers were removed from the
database before analysis. The Malawian National Health
Sciences Research Committee approved the use of data for
this analysis.
In January 2009, all adults (‡15 years old) treated with
ﬁrst-line antiretroviral regimens for more than 12 months,
who had more than one recorded CD4 cell measurement
after ART start and met at least one of the immunological
criteria of treatment failure, were identiﬁed. Results from
virological testing conﬁrmation were gathered over 1 year.
Pregnant women were excluded because interpretation of
absolute CD4 cell counts during pregnancy is problematic
because of haemodilution related to the progressive rise of
cortisol and plasma adenocorticotropine during the last
stage of pregnancy (Ekouevi et al. 2007; Lebon et al. 2007).
Laboratory methods and study deﬁnitions
Patient blood specimens were collected daily and CD4 cell
counts quantiﬁed at the Chiradzulu District Hospital using
Partec  ﬂow cytometry. Viral load testing was performed
by the DREAM laboratory (Blantyre, Malawi) using
bDNA for samples stored at )20  C for a maximum of
7 days (minimal detection threshold of 50 copies⁄ml).
Immunological failure was deﬁned as a decline in CD4
cell counts to or below treatment baseline values, decline
‡50% from on-treatment peak value or CD4 <100 cells⁄ll
after 12 months of therapy (Murri et al. 2006; WHO
2006). Pre-therapy baseline CD4 cell count was the
measurement closest in date and performed within
3 months of ART start. Virological failure was deﬁned as a
viral load >5000 copies⁄ml (>1000 in sensitivity analyses).
Prior conﬁrmation of immunological failure with a second
CD4 cell measurement, although recommended, was
inconsistently performed in the programme.
Statistical analysis
Standard summary statistics were used to describe the
proportion of patients diagnosed with immunological and
virological failure. The positive predictive value (PPV) of
immunologic failure was estimated as the proportion of
patients with >5000 copies⁄ml among those with available
viral load results and failure diagnosis. Values were
calculated for all patients and separately for patient with or
without repeat CD4 count testing for immunological
failure conﬁrmation. Exact binomial 95% conﬁdence
intervals (CI) were calculated. Sensitivity analyses using the
>1000 copies⁄ml threshold failure were ﬁnally performed.
Data were analysed in STATA version 10 (StataCorp,
College Station, TX, USA).
Results
In January 2009, a total of 7317 adults were receiving ﬁrst-
line ART for 1 year or more in the programme. Ninety-
seven percent had more than one CD4 cell count mea-
surement available during follow-up, and their initial CD4
cell count was 213 cells⁄ll [interquartile range, IQR 89–
213] (Table 1). A total of 357 (4.9%) patients were
diagnosed with immunological failure (Figure 1), and 66%
Table 1 Characteristics of patients receiving ART for >1 year
included and excluded from the analyses
Included
N = 7092
Excluded (no CD4
cell count)
N = 225
Men (%) 2108 (29.7) 71 (31.6)
Median age at
ART start, years [IQR]
35.1 [29.9–42.6] 36.0 [29.1–43.6]
ART-naı ¨ve at
therapy start (%)
6510 (91.8) 214 (95.1)
BMI <18.5 kg⁄m
2 (%) 2099 (29.6) 61 (27.1)
Tuberculosis treatment
at ART start (%)
188 (2.7) 7 (3.1)
Median CD4 cell count
at ART start [IQR]
213 [89–213] 182 [122–226.5]
3TC d4T NVP initial
regimen (%)
6699 (94.5) 211 (93.8)
Months of ART use [IQR] 31.6 [19.8–48.8] 13.4 [12.5–15.9]
3TC, lamivudine; ART, antiretroviral therapy; BMI, body mass
index; d4T, stavudine; IQR, interquartile range; NVP, nevirapine.
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330 (92.4%) patients were ART naı ¨ve, and 331 (92.7%)
received 3TC-d4T-NVP. Median CD4 cell count at ART
start was 182 cells⁄ll [IQR 87–260, n = 259]. At immu-
nological failure diagnosis, median time on ART was
25.2 months [IQR 12.5–47.7], median CD4 cell count
175 cells⁄ll [IQR 91–259] and 25 (7.0%) patients received
tuberculosis treatment.
CD4 cell testing was repeated for 315 (88.2%) patients,
59 within 3 months of the ﬁrst CD4 measurement. The
age, sex, time on ART and initial CD4 counts were similar
in patients with or without repeat CD4 cell counts (data
not shown). Although 130 (41.3%) patients with repeat
CD4 results no longer had immunological failure, ﬁve had
been already switched to second-line therapy without viral
load conﬁrmation. Of 185 patients with conﬁrmed immu-
nological failure, two died and one was lost to follow up
before viral load testing could be performed. Ninety-one
percent of patients had declines of CD4 count levels below
initial values, 88% a fall of 50% from on-treatment peak
values and 86% persistent levels below 100 cells⁄ll. Viral
load testing was performed for 138 (74.6%) patients.
Forty-nine patients (35.5% of the 138 tested) were
virologically suppressed, and 37 (26.8%) had >5000 cop-
ies⁄ml. Of patients with detectable viral load, 29 (32.6%)
were switched to a second-line regimen, eight of whom had
viral loads £5000 copies⁄ml. At the time of analysis,
however, 16 patients with viral loads >5000 had not been
switched to second line (two had defaulted and the others
were actively followed).
Of the 42 patients with no repeat CD4 count
measurement, four (9.5%) died and eight (19.0%)
defaulted before viral load was tested, and 17 (40.5%)
had viral load results. Twenty-nine (69.0%) patients had
No viral load testing 
N = 47 
Undetectable viral load 
N = 49 
Viral load (copies/ml) 
51 – 1000 = 39 
1001 – 5000 = 13 
>5000 = 37 
Immunological 
failure 
N = 185 
No immunological 
failure 
N = 130 
Viral load testing 
N = 17 
No viral load testing 
N = 25 
Immunological failure criteria 
N = 357
Patients with repeat 
CD4 count test 
N = 315 
Patients without repeat 
CD4 count test 
N = 42 
Patients receiving first line ART for ≥ ≥1 year in January 2009
N = 7317
Patients with >1 CD4 cell count result 
N = 7092
Viral load testing 
N = 138 
Undetectable viral load 
N = 4 
Viral load (copies/ml) 
51 – 1000 = 6 
1001 – 5000 = 0 
>5000 = 7 
Figure 1 Study proﬁle.
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4 ª 2011 Blackwell Publishing Ltddeclines of CD4 count levels below initial values, 19
(45.2%) a 50% fall from on-treatment peak values and
15 (35.7%) persistent levels <100 cells⁄ll. A total of four
patients (23.5%) were virologically suppressed, and 7
(41.2%) had viral load >5000 copies⁄ml. Six patients
were switched to second-line regimens, four with viral
load >5000 copies⁄ml.
Overall, patients with viral load testing had lower
median CD4 cell counts (119 vs. 238 cells⁄ll) and were
receiving ART for longer time periods (median of 47.4 vs.
28.2 months) than patients with viral load measurements
(Table 2). The positive predictive value of immunological
failure to identify virological failure among the 155
patients with viral load results, 138 with repeat and 17
without repeat CD4 count testing was 28.4% (95% CI
21.4–36.2%) (Table 3). It was 41.3% (95% CI 33.0–
50.0%) when the ‡1000 copies⁄ml viral load threshold
were used. Positive predictive values were higher among
patients with no repeat CD4 count measurement (41.2%
compared to 26.8%), but 95% conﬁdence intervals over-
lapped, and this analysis was based on small numbers
of patients.
Discussion
This ﬁeld evaluation in rural Malawi provided evidence of
the beneﬁt of routinely using viral load testing for
conﬁrmation of immunological failure before switching to
second-line therapy in HIV programmes of resource-
limited settings. In our analysis, only 28% of patients
diagnosed with immunological failure actually experienced
virological failure as deﬁned in the new WHO guidelines
(viral load >5000 copies⁄ml) (World Health Organization
2010).
In resource-limited settings where the rapid expansion
and scale-up of HIV programmes has necessitated a
simpliﬁed approach to ARV use, diagnosis and manage-
ment of treatment failure remain challenging. WHO
recommends using immunological failure criteria in
settings without access to viral load testing (World Health
Organization 2010). However, the use of the current
algorithm is likely to result in unnecessary early switching
of regimens. In our analysis, 34% of patients diagnosed
with immunological failure actually were virologically
suppressed. In the absence of virological conﬁrmation,
these patients might have been switched unnecessarily to
second line. Switching to a more costly second-line
regimen, currently not available in ﬁxed-dose combinations
(Me ´decins Sans Frontie `res 2010), is likely to compromise
long-term adherence because of increased pill burden and
consume limited ﬁnancial resources allocated to ART
programmes. Conﬁrmatory viral load testing, although
more costly than CD4 testing in the short term, can prevent
the unnecessary switching of many patients to second-line
therapy. This is particularly important in the current global
ﬁnancial climate with threatened ‘ﬂat-lining’ of HIV
funding. Furthermore, as HIV programmes age and expand
accurate diagnosis of patients, failing therapies will become
increasingly important to optimize patient management
and drug supply. Implementing the most cost-effective
strategies of patient management is therefore essential.
Findings of this analysis where virological failure was
deﬁned according to new WHO criteria (viral load
>5000 copies⁄ml) are consistent with results from
evaluations reporting poor performance of WHO immu-
nological failure criteria (Bisson et al. 2006; Moore et al.
2006; Badri et al. 2008; Mee et al. 2008; van Oosterhout
et al. 2009) based on the previous WHO deﬁnition of
virological failure (>10 000 threshold) (World Health
Organization 2006), although in areas where access to
viral load testing is limited because of cost or logistic
constraints, repeat CD4 count testing could allow
improved targeting of patients who are more likely to
experience virological failure. Indeed, three of seven
patients initially thought to meet immunological failure
criteria in our study did not require viral load testing and
were easily identiﬁed with this diagnostic algorithm.
This study was based on the analysis of routine moni-
toring data, and not all patients identiﬁed with immuno-
logical failure were tested for viral load in a timely manner
(68% of the individuals diagnosed during the study period).
Furthermore, patients without viral load conﬁrmatory
results had higher CD4 cell counts (median of 238 vs.
119 cells⁄ll) and were receiving ART for shorter time
periods (median of 28.2 vs. 47.4 months) than those with
viral load measurements. Because of these differences, we
might have under- or overestimated the positive predictive
valuesofimmunologicalfailurediagnosisinoursetting.The
large volume of patients treated in the programme of
Chiradzulu and the high patient⁄clinician ratio frequently
leave clinicians with limited time to consider alternative
Table 3 Positive predictive values (%) of immunological failure to
identify virological failure
Positive predictive value, %
Based on virological failure threshold
>5000 copies⁄ml >1000 copies⁄ml
Repeat CD4
cell count (n = 138)
26.8 (19.6–35.0) 36.2 (28.2–44.8)
No repeat CD4
cell count (n = 17)
41.2 (18.4–67.1) 41.2 (18.4–67.1)
All (n = 155) 28.4 (21.4–36.2) 41.3 (33.0–50.0)
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[e.g. presence of bacterial or parasitic infection or use of
corticosteroids (van Oosterhout et al. 2009)], and virolog-
ical failure might actually not reﬂect treatment failure in
some of the patients. Although this issue could contribute to
explain the poor performance of immunological and viro-
logical results, it is unlikely to be the only explanation; our
study primarily reﬂects the reality and difﬁculties of clinical
decision-making in resource-poor settings.
Conclusions
Our ﬁndings support the need to conﬁrm all cases of
immunological failure with viral load testing before
switching to second-line therapy. Developing simple,
reliable and affordable point-of-care tools for viral load
testing is essential to improve patient management and
optimize the use of resources in developing countries.
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